Immunocore Holdings Ltd Net Assets
Immunocore Holdings Ltd net assets. Based on the latest financial reports, Immunocore Holdings Ltd (IMCR) has net assets worth $419.80 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.12 Billion) and total liabilities ($699.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore IMCR year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $419.80 Million |
| % of Total Assets | 37.5% |
| Annual Growth Rate | 34.22% |
| 5-Year Change | 64.57% |
| 10-Year Change | 117.75% |
| Growth Volatility | 117.83 |
Net Assets of Immunocore Holdings Ltd (2013–2025)
Net assets of Immunocore Holdings Ltd from 2013 to 2025. This chart illustrates how Immunocore Holdings Ltd's net assets have evolved over time, based on quarterly financial data. See how leveraged is Immunocore Holdings Ltd's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Immunocore Holdings Ltd (2013–2025)
The table below shows the annual net assets of Immunocore Holdings Ltd from 2013 to 2025. For live market cap and overall valuation, see market value of Immunocore Holdings Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $381.03 Million | +5.63% |
| 2024-12-31 | $360.72 Million | -2.20% |
| 2023-12-31 | $368.84 Million | +8.83% |
| 2022-12-31 | $338.90 Million | +46.38% |
| 2021-12-31 | $231.53 Million | +318.33% |
| 2020-12-31 | $55.35 Million | +182.84% |
| 2019-12-31 | $19.57 Million | -65.42% |
| 2018-12-31 | $56.58 Million | -58.86% |
| 2017-12-31 | $137.55 Million | -21.39% |
| 2016-12-31 | $174.98 Million | -18.42% |
| 2015-12-31 | $214.50 Million | +10294.38% |
| 2014-12-31 | $-2.10 Million | -118.88% |
| 2013-12-31 | $11.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immunocore Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 80907931700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Immunocore Holdings Ltd Net Assets Breakdown (December 2025)
Immunocore Holdings Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $136.00K | 0.04% |
| Other Comprehensive Income | $-28.08 Million | -7.37% |
| Other Components | $1.24 Billion | 325.50% |
| Total Equity | $381.03 Million | 100.00% |
Immunocore Holdings Ltd Competitors by Market Cap
The table below lists competitors of Immunocore Holdings Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Melco Resorts & Entertainment Ltd
NASDAQ:MLCO
|
$1.50 Billion |
|
Globant SA
F:2G2
|
$1.50 Billion |
|
Valiant Co Ltd
SHE:002643
|
$1.50 Billion |
|
Sanbo Hospital Management Group Ltd. A
SHE:301293
|
$1.50 Billion |
|
Pavilion Real Estate Inv Trust
KLSE:5212
|
$1.50 Billion |
|
Thangamayil Jewellery Limited
NSE:THANGAMAYL
|
$1.50 Billion |
|
Guangdong Goworld Co Ltd
SHE:000823
|
$1.50 Billion |
|
Farglory Land Development Co Ltd
TW:5522
|
$1.50 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immunocore Holdings Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 360,716,000 to 381,033,000, a change of 20,317,000 (5.6%).
- Net loss of 26,418,662 reduced equity.
- Other comprehensive income increased equity by 5,679,000.
- Other factors increased equity by 41,056,662.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.42 Million | -6.93% |
| Other Comprehensive Income | $5.68 Million | +1.49% |
| Other Changes | $41.06 Million | +10.78% |
| Total Change | $- | 5.63% |
Book Value vs Market Value Analysis
This analysis compares Immunocore Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.03x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-0.95 | $30.49 | x |
| 2016-12-31 | $71.44 | $30.49 | x |
| 2017-12-31 | $55.93 | $30.49 | x |
| 2018-12-31 | $2.07 | $30.49 | x |
| 2019-12-31 | $0.72 | $30.49 | x |
| 2020-12-31 | $1.74 | $30.49 | x |
| 2021-12-31 | $5.28 | $30.49 | x |
| 2022-12-31 | $7.41 | $30.49 | x |
| 2023-12-31 | $7.54 | $30.49 | x |
| 2024-12-31 | $7.22 | $30.49 | x |
| 2025-12-31 | $7.57 | $30.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immunocore Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.88%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 2.80x
- Recent ROE (-6.93%) is above the historical average (-81.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -123.04% | -180.63% | 0.10x | 6.52x | $-3.99 Million |
| 2014 | 0.00% | -87.70% | 0.10x | 0.00x | $-5.38 Million |
| 2015 | 6.27% | 117.43% | 0.04x | 1.28x | $-8.00 Million |
| 2016 | -13.22% | -140.50% | 0.08x | 1.25x | $-40.63 Million |
| 2017 | -36.04% | -343.13% | 0.07x | 1.44x | $-63.32 Million |
| 2018 | -126.60% | -302.82% | 0.12x | 3.46x | $-77.29 Million |
| 2019 | -531.13% | -404.89% | 0.10x | 12.57x | $-105.89 Million |
| 2020 | -133.87% | -246.04% | 0.15x | 3.56x | $-79.63 Million |
| 2021 | -57.64% | -493.45% | 0.07x | 1.76x | $-156.60 Million |
| 2022 | -12.83% | -30.13% | 0.27x | 1.55x | $-77.35 Million |
| 2023 | -11.86% | -22.17% | 0.33x | 1.62x | $-80.64 Million |
| 2024 | -11.31% | -16.45% | 0.25x | 2.80x | $-76.88 Million |
| 2025 | -6.93% | -8.88% | 0.28x | 2.80x | $-64.52 Million |
Industry Comparison
This section compares Immunocore Holdings Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immunocore Holdings Ltd (IMCR) | $419.80 Million | -123.04% | 1.67x | $1.50 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Immunocore Holdings Ltd
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more